Effects of intermittent treatment with parathyroid hormone (PTH) on osteoblastic differentiation and mineralization of mouse induced pluripotent stem cells in a 3D culture model.
atelocollagen
induced pluripotent stem cells
osteoblastic differentiation
parathyroid hormone
Journal
Journal of periodontal research
ISSN: 1600-0765
Titre abrégé: J Periodontal Res
Pays: United States
ID NLM: 0055107
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
25
11
2019
revised:
10
04
2020
accepted:
24
04
2020
pubmed:
26
6
2020
medline:
15
12
2020
entrez:
26
6
2020
Statut:
ppublish
Résumé
PTH plays an important role in bone remodeling, and different actions have been reported depending on its administration method. iPSCs are promising as a cell source for regeneration of periodontal tissue due to their ability of proliferation and pluripotency. However, the effects of PTH on iPSCs remain mostly unknown. The purpose of this study was to investigate in vitro effects of parathyroid hormone (PTH) on osteoblastic differentiation of induced pluripotent stem cells (iPSCs) in a 3D culture model. Following embryoid body (EB) induction from mouse iPSCs (miPSCs), dissociated cells (miPS-EB-derived cells) were seeded onto atelocollagen sponge (ACS) in osteoblast differentiation medium (OBM). Cell-ACS constructs were divided into three groups: continuous treatment with human recombinant PTH (1-34) (PTH-C), intermittent PTH treatment (PTH-I) or OBM control. To confirm the expression of PTH receptor-1(PTH1R), the expression of Pth1r and cAMP production over time were assessed. Real-time PCR was used to assess the expression of genes encoding osterix (Sp7), runt-related transcription factor 2 (Runx2), collagen type 1 (Col1a1), and osteocalcin (Bglap) at different time points. Mineralization was assessed by von Kossa staining. Histochemical staining was used to analyze alkaline phosphatase (ALP) activity, and immunolocalization of SP7 and BGLAP was analyzed by confocal laser scanning microscopy (CLSM). On days 7 and 14, expression of the Pth1r in miPS-EB-derived cells was increased in all groups. Production of cAMP, the second messenger of the PTH1R, tended to increase in the PTH-I group compared with PTH-C group on day 14. Expression of Col1a1 in the PTH-I group on day 14 was significantly higher than other groups. There was a time-dependent increase in the expression of Sp7 in all groups. On day 14, the expression level of Sp7 in the PTH-I group was significantly higher than other groups. In von Kossa staining, the PTH-I group showed higher level of staining compared with other groups on day 14, whereas the level was slightly attenuated in the PTH-C group. In histochemical staining, ALP-positive cells were significantly increased in the PTH-I group compared with other groups on day 14. In CLSM analysis, the numbers of SP7- and BGLAP-positive cells showed a gradual increase over time, and on day 14, a significantly greater SP7 expression was observed in the PTH-I group than other groups. These results suggested that the intermittent PTH treatment promotes osteoblastic differentiation and mineralization of miPSCs in the ACS scaffold.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
PTH plays an important role in bone remodeling, and different actions have been reported depending on its administration method. iPSCs are promising as a cell source for regeneration of periodontal tissue due to their ability of proliferation and pluripotency. However, the effects of PTH on iPSCs remain mostly unknown. The purpose of this study was to investigate in vitro effects of parathyroid hormone (PTH) on osteoblastic differentiation of induced pluripotent stem cells (iPSCs) in a 3D culture model.
MATERIALS AND METHODS
METHODS
Following embryoid body (EB) induction from mouse iPSCs (miPSCs), dissociated cells (miPS-EB-derived cells) were seeded onto atelocollagen sponge (ACS) in osteoblast differentiation medium (OBM). Cell-ACS constructs were divided into three groups: continuous treatment with human recombinant PTH (1-34) (PTH-C), intermittent PTH treatment (PTH-I) or OBM control. To confirm the expression of PTH receptor-1(PTH1R), the expression of Pth1r and cAMP production over time were assessed. Real-time PCR was used to assess the expression of genes encoding osterix (Sp7), runt-related transcription factor 2 (Runx2), collagen type 1 (Col1a1), and osteocalcin (Bglap) at different time points. Mineralization was assessed by von Kossa staining. Histochemical staining was used to analyze alkaline phosphatase (ALP) activity, and immunolocalization of SP7 and BGLAP was analyzed by confocal laser scanning microscopy (CLSM).
RESULTS
RESULTS
On days 7 and 14, expression of the Pth1r in miPS-EB-derived cells was increased in all groups. Production of cAMP, the second messenger of the PTH1R, tended to increase in the PTH-I group compared with PTH-C group on day 14. Expression of Col1a1 in the PTH-I group on day 14 was significantly higher than other groups. There was a time-dependent increase in the expression of Sp7 in all groups. On day 14, the expression level of Sp7 in the PTH-I group was significantly higher than other groups. In von Kossa staining, the PTH-I group showed higher level of staining compared with other groups on day 14, whereas the level was slightly attenuated in the PTH-C group. In histochemical staining, ALP-positive cells were significantly increased in the PTH-I group compared with other groups on day 14. In CLSM analysis, the numbers of SP7- and BGLAP-positive cells showed a gradual increase over time, and on day 14, a significantly greater SP7 expression was observed in the PTH-I group than other groups.
CONCLUSION
CONCLUSIONS
These results suggested that the intermittent PTH treatment promotes osteoblastic differentiation and mineralization of miPSCs in the ACS scaffold.
Substances chimiques
Parathyroid Hormone
0
Receptor, Parathyroid Hormone, Type 1
0
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-743Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18H03007 (TA)
Organisme : Japan Society for the Promotion of Science
ID : 18K17056 (AH)
Organisme : Multidisciplinary Research Center for Jaw Disease (MRCJD), Tokyo Dental College, Tokyo, Japan (a MEXT Private University Research Branding Project)
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Listgarten MA. Pathogenesis of periodontitis. J Clin Periodontol. 1986;13:418-425.
Slots J, Genco RJ. Microbial pathogenicity. Black-pigmented Bacteroides species, Capnoeythophaga species, and Actinobacillus actinomyeetemeomitans in human periodontal disease: virulence factors in colonization, survival, and tissue destruction. J Dent Res. 1984;63:412-421.
Kao RT, Nares S, Reynolds MA. Periodontal regeneration - intrabony defects: a systematic review from the AAP Regeneration Workshop. J Periodontol. 2015;86:S77-S104.
Kawaguchi H, Hirachi A, Hasegawa N, et al. Enhancement of periodontal tissue regeneration by transplantation of bone marrow mesenchymal stem cells. J Periodontol. 2004;75:1281-1287.
Kim SH, Kim KH, Seo BM, et al. Alveolar bone regeneration by transplantation of periodontal ligament stem cells and bone marrow stem cells in a canine peri-implant defet model: a pilot study. J Periodontal. 2009;80:1815-1823.
Ding G, Liu Y, Wang W, et al. Allogeneic periodontal ligament stem cell therapy for periodontitis in swine. Stem Cells. 2010;28:1829-1838.
Lin Z, Rios HF, Cochran DL. Emerging regenerative approaches for periodontal reconstruction: a systematic review from the AAP Regeneration Workshop. J Periodontol. 2015;86:S134-S152.
Hasegawa N, Kawaguchi H, Hirachi A, et al. Behavior of transplanted bone marrow-derived mesenchymal stem cells in periodontal defects. J Periodontol. 2006;77:1003-1007.
Hynes K, Menicanin D, Han J, et al. Mesenchymal stem cells from iPS cells facilitate periodontal regeneration. J Dent Res. 2013;92:833-839.
Thomson JA, Eldor JI, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-1147.
Drukker M, Katchman H, Katz G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immunorejection than adult cells. Stem Cells. 2006;24:221-229.
Ochiai-Shino H, Kato H, Sawada T, et al. A novel strategy for enrichment and isolation of osteoprogenitor cells from induced pluripotent stem cells based on surface maker combination. PLoS ONE. 2014;9:e99534.
Hisanaga Y, Suzuki E, Aoki H, et al. Effect of the combined use of enamel matrix derivative and atelocollagen sponge scaffold on osteoblastic differentiation of mouse induced pluripotent stem cells in vitro. J Periodontal Res. 2018;53:240-249.
Armen HT Jr, Robert FG. Perspective teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006;21:354-365.
Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363:2396-2405.
Pines M, Fukayama S, Costas K, et al. Inositol 1-,4-,5-trisphosphate-dependent Ca2+ signaling by the recombinant human PTH/PTHrP receptor stably expressed in a human kidney cell line. Bone. 1996;18:381-389.
Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol. 2015;22:41-50.
Reeve J, Hesp R, Williams D, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet. 1976;7968:1035-1038.
Tam CS, Heersche JM, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;2:506-512.
Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;6:1434-1446.
Etoh M, Yamaguchi A. Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone. J Bone Miner Metab. 2010;6:641-649.
Yu B, Zhao X, Yang C, et al. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J Bone Miner Res. 2012;9:2001-2014.
Wang X, Wang Y, Dai X, et al. Effects of intermittent administration of parathyroid hormone (1-34) on bone differentiation in stromal precursor antigen-1 positive human periodontal ligament stem cells. Stem Cells Int. 2016;2016:4027542.
Li Y, Hu Z, Zhou C, et al. Intermittent parathyroid hormone (PTH) promotes cementogenesis and alleviates the catabolic effects of mechanical strain in cementoblasts. BMC Cell Biol. 2017;18:19).
Ishizuya T, Yokose S, Hori M, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest. 1997;99:2961-2970.
Ye T, Xu Y, Fu Q, He M. Parathyroid hormone regulates osteoblast differentiation in a Wnt/β-catenin-dependent manner. Mol Cell Biochem. 2011;355:211-216.
Muroi Y, Kakudo K, Nakata K. Effects of compressive loading on human synovium- derived cells. J Dent Res. 2007;86:786-791.
Shinohara Y, Nakamura T, Shirakata Y, Noguchi K. Bone healing capabilities of recombinant human bone morphogenetic protein-9 (rhBMP-9) with a chitosan or collagen carrier in rat calvarial defects. Dent Mater J. 2016;35:454-460.
Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009;5:734-742.
Chandra A, Lin T, Zhu J, et al. PTH1-34 blocks radiation-induced osteoblast apoptosis by enhancing DNA repair through canonical Wnt pathway. J Biol Chem. 2015;290:157-167.
Kawamoto T, Kawamoto K. Preparation of thin frozen sections from nonfixed and undecalcified hard tissues using Kawamot’s film method. Methods Mol Biol. 2014;130:149-164.
Rios HF, Lin Z, Oh B, Park CH, Giannobile WV. Cell-and gene-based therapeutic strategies for periodontal regenerative medicine. J Periodontol. 2011;82:1223-1237.
Zujur D, Kanke K, Lichtler AC, Hojo H, Chung U, Ohba S. Three-dimensional system enabling the maintenance and directed differentiation of pluripotent stem cells under defined conditions. Sci Adv. 2017;3:e1602875.
Nisida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994;15:717-723.
Chen B, Lin T, Yang X, Li Y, Xie D, Cui H. Intermittent parathyroid hormone (1-34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway. Exp Ther Med. 2016;22:2399-2406.
Mrozik KM, Gronthos S, Menicanin D, Marino V, Bartold PM. Effect of coating Straumann® Bone Ceramic with Emdogain on mesenchymal stromal cell hard tissue formation. Clin Oral Investig. 2012;16:867-878.
Ferrari SL, Behar V, Chrev M, Rosenblatt M, Bisello A. Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves β-arrestin 2. J Bio Chem. 1999;42:29968-29975.
Sneddon BW, Syme CA, Bisello A, et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Bio Chem. 2003;44:43787-43796.
Chauvin S, Bencsik M, Bambino T, Nissenson RA. Parathyroid hormone receptor recycling: role of receptor dephosphorylation and β-arrestin. Mol Endocrinol. 2002;16:2720-2732.
Tian J, Smogorzewski M, Kedes L, Massry SG. PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. Am J Nephrol. 1994;14:41-46.
Urena P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int. 1994;45:605-611.
Ferrari SL, Bisello A. Cellular distribution of constitutively active mutant parathyroid hormone (PTH)/PTH-related protein receptors and regulation of cyclic adenosine 3’,5’-monophosphate signaling by β-arrestin2. Mol Endocrinol. 2001;15:149-163.
Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. J Bio Chem. 2001;276:19452-19460.
Buttery LDK, Bourne S, Xynos JD, et al. Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Eng Part A. 2004;7:89-99.
Ferrer SM, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829-836.
Li F, Bronson S, Niyibizi C. Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage. J Cell Biochem. 2010;109:643-652.
Verjans ET, Doijen J, Luyten W, Landuyt B, Schoofs L. Three-dimensional cell culture models for anticancer drug screening: Worth the effort? J Cell Physiol. 2018;233:2993-3003.
Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010;31:8494-8506.